Paritaprevir is an HCV NS3/4A protease inhibitor used in combination therapy to treat chronic hepatitis C virus infection by inhibiting viral replication. The Paritaprevir category includes the parent… Read more
Paritaprevir is an HCV NS3/4A protease inhibitor used in combination therapy to treat chronic hepatitis C virus infection by inhibiting viral replication. The Paritaprevir category includes the parent active pharmaceutical ingredient alongside its stable isotope labelled analogue, Paritaprevir-d5, which are essential tools for pharmaceutical analysis. Laboratories utilize these high-quality reference standards for impurity profiling, method validation, and rigorous quality control protocols. By providing a deuterated internal standard, the labelled compound allows for accurate quantification of the drug in complex biological matrices using mass spectrometry-based assays. Researchers and analytical chemists rely on these reference materials to ensure the precision and consistency of bioanalytical methods, supporting regulatory compliance and the reliable assessment of therapeutic drug concentrations during development and stability testing.